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ABSTRACT
Tumors infected with a recombinant defective adenovirus expressing interleukin 12 (IL-12) undergo regres-
sion, associated with a cytotoxic T lymphocyte (CTL)-mediated antitumor immune response. In the present
study we generated anti-CT26 CTLs by short-term coculture of CT26 cells and lymph node cells obtained
from mice harboring subcutaneous CT26 tumors injected with an adenoviral vector expressing IL-12 (Ad-
CMVIL-12), control adenovirus (AdCMVlacZ), or saline. Regression of small intrahepatic CT26 tumors in
unrelated syngeneic animals was achieved with CTLs derived from mice whose subcutaneous tumors had been
injected with AdCMVIL-12 but not with CTLs from the other two control groups. The necessary and suffi-
cient effector cell population for adoptive transfer consisted of CD8 1 T cells that showed anti-CT26 speci-
ficity partly directed against the AH1 epitope presented by H-2Ld. Interestingly, treatment of a subcutaneous
tumor nodule with AdCMVIL-12, combined with intravenous adoptive T cell therapy with short-term CTL
cultures, had a marked synergistic effect against large, concomitant live tumors. Expression of IL-12 in the
liver in the vicinity of the hepatic tumor nodules, owing to spillover of the vector into the systemic circula-
tion, appeared to be involved in the increased in vivo antitumor activity of injected CTLs. In addition, adop-
tive T cell therapy improved the outcome of tumor nodules transduced with suboptimal doses of AdCMVIL-
12. Our data provide evidence of a strong synergy between gene transfer of IL-12 and adoptive T cell therapy.
This synergy operates both at the induction and effector phases of the CTL response, thus providing a ratio-
nale for combined therapeutic strategies for human malignancies.
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OVERVIEW SUMMARY
Evidence that the IL-12 gene, transferred into tumors by
adenovirus, displays antitumor activity is well confirmed,
and this activity has been shown to involve immune and
nonimmune mechanisms. IL-12 bioactivity results in a po-
tent induction of tumor-specific CTLs that can be used for
adoptive T cell therapy. This study demonstrates that IL-
12 intratumor gene transfer and adoptive T cell therapy are
synergistic to the treatment of experimental transplantable
colon cancer. Synergy includes not only the facilitation of
CTL obtention but also mechanisms of cooperation at the
effector phase of the combined therapy. This synergy seems
to be highly beneficial in the treatment of established
metastatic disease.
INTRODUCTION
AD OPTIV E CEL LU LA R T HER APY is defined as the infusion ofimmune effector cells for the treatment and/or prevention
of a disease (Riddell and Greenberg, 1995; Yee et al., 1997).
Different types of T cell populations have been used to treat vi-
ral infections and tumors in murine models (Kast et al., 1989;
Lynch and Miller, 1991), leading to their use in the clinic (Rid-
dell et al., 1992; Rossemberg et al., 1994; Henslop et al., 1996).
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A major hurdle for the feasibility of T cell adoptive therapy in
oncology is the availability of tumor-specific T cells for in vitro
expansion and differentiation into effector populations (Kast et
al., 1989; Lynch and Miller, 1991; Riddell et al., 1992; Rossem-
berg et al., 1994; Riddell and Greenberg, 1995; Henslop et al.,
1996; Yee et al., 1997). Passive immunotherap y using T cells
relies on the culture of autologous lymphocytes in the presence
of a source of tumor antigens, professional antigen-presenting
cells (APCs) and growth factors (Lynch and Miller, 1991; Yee
et al., 1997). Low numbers of T cell precursors in tumor hosts
could be simply a consequence of the lack of an ongoing anti-
tumor response (Melero et al., 1997b; Wick et al., 1997) or the
result of immune-suppressiv e mechanisms, displayed by the
malignancy, that could lead to antigen-specific tolerance
(Speiser et al., 1997; Chen, 1998).
The endogenous cellular immune response against tumor
antigens can be boosted by a number of strategies, including
vaccination with different formulations containing tumor anti-
gens or by the administration of certain cytokines (Chen et al.,
1993). The most successful procedures of active immunother-
apy include: artificial presentation of tumor antigens on pro-
fessional APCs or genetic modifications of tumor cells to mimic
the functions of professional antigen-presentin g cells when pro-
ducing cytokines and/or when expressing membrane-bound
costimulatory molecules (cytokines) (Chen et al., 1993; May-
ordomo et al., 1995).
Interleukin 12 (IL-12) is a cytokine with potent antitum or ef-
fects that result from its ability to stimulate cytotoxic T cells
(CTLs), type 1 helper T cells (Th1 cells), and natural killer (NK)
cells (Shurin et al., 1997) and to trigger a cascade of mediators
that ultimately impair tumor angiogenesis (Siders et al., 1998;
Tannenbaum et al., 1998). IL-12 has been delivered in vivo into
the tumor environment by different recombinant viral vectors
(Caruso et al., 1996; Toda et al., 1998), achieving tumor re-
gressions and upregulation of the cellular immune response
against malignant cells (Caruso et al., 1996; Toda et al., 1998).
The intimate mechanisms behind IL-12 antitumor activity in-
volve immune and nonimmune phenomena. Experimentati on
has shown that interferon g (IFN- g ), a major downstream me-
diator of IL-12 antitumor activity, is able to inhibit angiogene-
sis in malignant lesions through the induction of chemokines
such as IFN-g inducible protein 10 (IP-10) (Siders et al., 1998).
In some cases these mechanisms seem to be operational in the
absence of conventional T cells (Boggio et al., 1998; Siders et
al., 1998; Tannenbaum  et al., 1998).
Recombinant defective adenoviruses have been shown to be
an excellent vehicle to deliver IL-12 to experimental tumors in-
cluding a poorly immunogenic  colon carcinoma (Caruso et al.,
1996; Mazzolini et al., 1999). In our hands, high levels of IL-
12 are produced on intratumoral injection of AdCMVIL-12 in
CT26-derived tumors, leading to complete tumor regressions in
60–80% of cases. In such cases, a potent antitumor CTL re-
sponse was detected, depletion of CD8 1 cells abrogated the
therapeutic effect, and a lymphocyte infiltrate accompanied tu-
mor regressions (Mazzolini et al., 1999).
These findings provided the rationale for protocols of com-
bination immunotherapy  in which gene transfer with Ad-
CMVIL-12 promotes the in vivo expansion of antitumor CTLs,
thereby facilitating their subsequent in vitro culture for adop-
tive transfer. Our data demonstrate that active immunotherapy
with AdCMVIL-12 not only permits CTL adoptive transfer by
simplifying the obtention of the effector cells, but also syner-
gizes with adoptive T cell therapy at the effector phase when
both therapeutic strategies are used together to treat metastatic
disease.
MATERIALS AND METHODS
Animals, cell culture, and reagents
Five- to 8-week-old BALB/c female mice were purchased
from Charles River (Barcelona, Spain) and were housed ac-
cording to institutional guidelines.
The 293 cell line (adenoviral E1-transformed  human em-
bryonic kidney cells) was obtained from American Type Cul-
ture Collection (ATCC, Rockville, MD). The BALB/c (H-2d)
mouse-derived CT26 tumor cell line is an undifferentiated
murine colorectal adenocarcinoma  (Brattain et al., 1980) that
was established from an N-nitroso-N-methylurethane -induced
transplantable tumor (Corbett et al., 1975), obtained from K.
Brand (Max-Planck-Institu t fur Biochemie, Munich, Germany).
P815 and YAC-1 cells were obtained through the ATCC. The
293 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heat-inactivated fe-
tal calf serum (FCS), 2 mM L-glutam ine, streptomycin (100
U/ml), and penicillin (100 m g/ml), CT26 cells were maintained
in RPMI 1640 medium identically supplemented. Cell culture
reagents were from GIBCO (Basel, Switzerland).
Construction of adenovirus
Recombinant adenovirus carrying IL-12 (AdCMVIL-12) has
been previously described (Mazzolini et al., 1999). Briefly, an
expression cassette of IL-12 under the control of the cy-
tomegalovirus (CMV) promoter was constructed encom passing
IL-12 p35 cDNA, an internal ribosomal entry site (IRES), IL-
12 p40 cDNA, and a polyadenylation signal. Recombinant ade-
novirus encoding the IL-12 cassette of expression was gener-
ated by cotransfection of 293 cells according to standard
procedures (Qian et al., 1995). Adenovirus carrying the lacZ
reporter gene under the control of the CMV promoter (Ad-
CMVlacZ) was produced similarly. Recombinant adenoviruses
were isolated from a single plaque, expanded in 293 cells, and
purified by double cesium chloride ultracentrifugation  (Qian et
al., 1995). Purified virus was extensively dialyzed against 10
mM Tris–1 mM MgCl2 and stored in aliquots at 2 80°C, and it
was carefully titrated by plaque assay.
Peptides
The H2-Ld-restricted peptides AH1 (SPSYVYHQF) (Huang
et al., 1996) and P815AB (LPYLGWLVF) (Van den Eynde et
al., 1991) were synthesized by 9-fluorenylmeth oxycarbonyl
(Fmoc) chemistry as described (Prieto et al., 1995) and their
purity confirm ed by high-performan ce liquid chromatography
(HPLC).
T cell culture
Mice carrying bilateral 5- to 8-mm (diam eter) subcutaneous
CT26 tumors were treated by intratumor injections of 108 PFU
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of AdCMVIL-12 or control adenovirus (AdCMVlacZ), or were
left untreated. Draining lymph nodes were removed aseptically
5 days later and single-cell suspensions were obtained by press-
ing the lymph nodes mechanically through mesh screens.
Lymph node cells were cultured in 24-well plates (Greiner
Labortechnik, Frickenhausen, Germany) for 7 days at 5 3 106
cells/well with 2 3 105 CT26 tumor cells/well pretreated for 1
hr at 37°C with mitomycin C (150 m g/ml; Sigma, Madrid,
Spain), a reagent that was extensively washed. Culture medium
was complete RPMI 1640 supplemented on day 5 with murine
IL-2 (mIL-2, 8–10 IU/ml; Peprotech, London, UK).
51Cr release assay
Cytotoxicity was analyzed in conventional 5-hr 51Cr-release
assays as described (Melero et al., 1997a). Briefly, 51Cr-loaded
CT26, P815, and YAC-1 cells were incubated with effector cells
at different effector-to-target (E:T) ratios in triplicate wells and
51Cr release (cpm) into the supernatants was measured in a g
counter to calculate percent specific release as described
(Melero et al., 1997b). In some experim ents, P815 cells were
incubated during the assay with various concentrations of AH1
or P815AB peptide.
Immunofluorescence and flow cytometry
Double immunofluore scence staining with fluorescein iso-
thiocyanate (FITC)-conjugated anti-CD8 and phycoerythrin
(PE)-conjugate d anti-CD4 (PharMingen- Becton Dickinson, San
Diego, CA) was carried out as previously described (Melero et
al., 1997b). Electronically gated lymphocytes were analyzed on
a FACscan (Becton Dickinson, Mountain View, CA).
In vivo treatment of CT26 tumors with recombinant
adenovirus and adoptive transfer of lymphocytes
BALB/c mice, in groups of seven or eight, were injected sub-
cutaneously in the right hand flank with 5 3 105 CT26 cells in
25 m l of phosphate-buffered  saline (PBS). In some experiments,
mice received in addition an identical dose of tumor cells in-
jected surgically in the midlobe of the liver under general anes-
thesia. Subcutaneous tumors were injected with 108 PFU of re-
combinant adenovirus in 50 m l of PBS. For cellular adoptive
therapy, mice were injected intravenously with 5 3 106 cells
from short-term CTL lines and given three intraperitoneal in-
jections of 2 3 104 human recombinant IL-2 (Chiron,
Emeryville, CA) in PBS on alternate days. Tumor size (mean
diameter) was assessed by laparotomy, using a precision caliper.
Statistical significance of the differences among groups was
evaluated by Mann–Whitney tests for tumor sizes and log-rank
test for survival.
Immunomagnetic selection of CD8 1 T cells and
negative selection with MAb plus complement
Cells from short-term CTL cultures were incubated with anti-
CD8-coated magnetic beads according to manufacturer in-
structions (Miltenyi Biotec, Bergisch Gladbach, Germany) and
purified on a mini-MACS column (Miltenyi). Purity of CD8 1
cells was 98% as shown by fluorescence activated cell sorting
(FACS) analysis. Depletion of CD41 or CD8 1 cells was
achieved by treatment with culture supernatants from the hy-
bridomas GK1.5 and H35.17.2 (ATCC) and rabbit complement
(Sigma). Effectiveness of the procedure was routinely checked
by FACS.
IL-12 p70 quantitative assay
To evaluate the production of IL-12 by the liver parenchyma
and subcutaneous tumor, we injected AdCMVIL-12, Ad-
CMVlacZ, or saline into subcutaneous tumors. Three days later,
tissues were collected for determination of IL-12 p70 concen-
tration by enzyme-linked immunosorben t assay (ELISA). To
estimate the in vivo production of cytokines 3 days after treat-
ment of the tumors with adenoviruses, liver and subcutaneous
tumors were removed and frozen in liquid nitrogen. Frozen tis-
sue was homogenized in 0.5 ml of PBS containing 100 m M
phenylmethylsu lfonyl fluoride (PMSF) and aprotinin (10
m g/ml; ICN Biomedicals) by Ultra-Turrax (Labortechnik,
Staufen, Germany). The homogenate was then sonicated for 10
sec and cleared of debris by centrifugation in a microcentrifuge
for 5 min at 4°C. Samples were stored at 2 20°C.
The ELISA for IL-12 p70 was performed with a commer-
cial kit (Endogen, Woburn, MA) according to manufacturer in-
structions, using superblocking buffer (Pierce, Rockford, IL).
X-Gal histochemical staining
Mice bearing both a subcutaneous and intrahepatic tumors
were anesthetized with a mixture of ketam ine and xylazine. Ad-
CMVlacZ (5 3 108 PFU) in 50 m l of saline was injected into
the subcutaneous tumor. Two days later, animals were sacri-
ficed and the livers were excised and immediately embedded
in O.C.T. compound (Tissue Tek, Zoeterwoude, The Nether-
lands) and frozen in liquid nitrogen. Sections of 6- m m thick-
ness were fixed with glutaraldehyde (0.5% ) and stained with 5-
bromo-4-chloro- 3-indolyl- b -D -galactopyranoside  (X-Gal) as
described previously (Qian et al., 1997).
RESULTS
AdCMVIL-12 induces tumor regression and raises
CTLs for adoptive therapy
rIL-12 delivered by gene transfer procedures into tumors has
been shown to inhibit tumor growth and to induce tumor re-
gressions (Caruso et al., 1996; Toda et al., 1998). In our hands
(Mazzolini et al., 1999), locally delivered AdCMVIL-12 in-
duced the production of significant levels of IL-12 and dis-
played a potent effect against the CT26 colon carcinom a cell
line forming either subcutaneous or intraheptic tumor nodules.
In 60–80% of cases complete regressions were observed that
were associated with an increase in tumor-specific CTL activ-
ity. Typically, a 5- to 8-mm (diameter) CT26 subcutaneous nod-
ule treated with 108 PFU of AdCMVIL-12 started to regress
during the next 4–6 days, unless the mouse had been treated
with a depleting anti-CD8 monoclonal antibody (MAb), condi-
tions under which the antitumor effect was completely abro-
gated. Surgical and pathological examination revealed enlarged
draining lymph nodes and an infiltrate of lymphocytes into the
tumor. Accordingly, it was hypothesized that the obtention of
CTL cultures aimed for adoptive therapy would be efficiently
simplified in such animals.
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Since the CT26 cell line was derived from an adenocarci-
noma arising from the colon, we established models in which
5 3 105 tumor cells were directly injected into the midlobe of
the liver to give rise to intrahepatic tumors. These malignant
nodules resemble those frequently observed in advanced human
colon cancers. This model was employed to test whether treat-
ment of CT26 tumors with AdCMVIL-12 would allow the gen-
eration of CTL cultures to be used in simple adoptive therapy
protocols. Groups of four mice were injected subcutaneously
and bilaterally with 5 3 105 CT26, and after 10 days tumors
(4–8 mm in diameter) were injected with AdCMVIL-12, a con-
trol recombinant adenovirus encoding b -galactosidase (Ad-
CMVlacZ), or saline. Seven days later, mice were killed and
cell suspensions of their draining lymph nodes were cocultured
for 7 days with mitomicin C-treated CT26 cells. Such cell cul-
tures were subsequently injected intravenously (5 3 106
cells/mouse) into mice hosting CT26 tumor cells inside their
livers for 4 days prior to adoptive transfer. The adoptive trans-
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FIG. 1. Intratumoral injection of AdCMVIL-12 raises CTL cultures effective for adoptive therapy. CTL cultures were set up by
coculturing mitomycin C-treated CT26 cells with mononuclear cells from draining lymph nodes of mice bearing 4- to 8-mm sub-
cutaneous CT26 tumors previously treated by intratumoral injections of 108 PFU of AdCMVIL-12, 108 PFU of AdCMVlacZ, or
saline buffer. Three groups of mice, which had been injected with 5 3 105 viable CT26 cells in the midlobe of the liver on day 0,
were given on day 4 5 3 106 cells from each of the corresponding CTL cultures. Treatment was completed in every group by three
doses (on alternate days) of 2 3 104 IU of hrIL-2. Tumor size (a) was assessed by surgical examination on day 14 and survival was
monitored thereafter (b). Results were reproducible in three different experiments similarly performed (data not shown).
a)
b)
fer of cells was supported in every case by the intraperitoneal
injection of three doses of 2 3 104 IU of rIL-2 every 2 days to
support the effect of injected T cells, as formerly described for
these types of therapeutic regimens (Kast et al., 1989; Lynch
and Miller, 1991). As shown in Fig. 1, only those mice into
which were transferred CTL cultures obtained from mice treated
with AdCMVIL-12 showed a marked decrease in tumor growth
as assessed 14 days later by surgical examination. Follow-up
survival studies of such animals showed slower tumor pro-
gression, in most instances with 40–60% tumor eradications de-
pending on the experiment (Fig. 1b). In some cases, the liver
tumors observed in mice treated with CTLs obtained from the
AdCMVlacZ groups were slightly smaller than those of mice
treated with CTLs from the saline-treated groups, but complete
regressions did not occur, nor was a clear extension of survival
observed. It is worth mentioning that mice treated with CTL
cultures from the lymph nodes of the saline control groups de-
veloped multiple peritoneal tumors that were not observed in
the other groups, indicating that adoptive transfer had had a
therapeutic effect to prevent or control these kinds of metas-
tases (data not shown).
In conclusion, delivery of IL-12 by recombinant adenovirus
allowed the induction of effective CTL populations for adop-
tive therapy.
CD8 1 cells mediate the antitumor effect
Our 7-days cocultures of lymph node cells from mice whose
tumors had been treated with AdCMVIL-12 and nonproliferat-
ing CT26 cells contained cellular mixtures with 20–50% CD8 1
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FIG. 2. Adoptively transferred T cell cultures contain anti-CT26-spe cific CTL activity. (a) FACS analysis after double stain-
ing by immunofluores cence with anti-CD4/anti-CD8 MAbs of a CTL culture obtained from mice whose subcutaneous CT26 tu-
mors had been treated with AdCMVIL-12 as in Fig. 1. (b) Specific lysis against CT26 measured by standard 51Cr release assays
of CTL cultures obtained from mice bearing subcutaneous CT26 tumors injected with 108 PFU of AdCMVIL-12 (circles) or Ad-
CMVlacZ (squares). (c) Specific lysis of P815 cells pulsed during a 51Cr release assay with 1 m M AH1 peptide (squares) or 1
m M control irrelevant peptide (circles), or left unpulsed (diamonds), mediated by CTL cultures derived from mice whose tumors




T lymphocytes (Fig. 2a). Such lymphocyte populations dis-
played specific cytolytic activity against CT26, in contrast with
cultures derived from mice bearing AdCMVlacZ- or saline-
treated tumors. Indeed, CT26 cells were efficiently killed in
vitro while the P815 mastocytoma cell line bearing identical
MHC molecules was not (Fig. 2b). None of the cultures sig-
nificantly lysed YAC-1 cells, indicating that NK activity was
low in those lymphocyte cultures (data not shown). CTL clones
obtained from mice immunized with CT26 granulocyte-
macrophage colony-stimulati ng factor (GM-CSF) transfectants
have been used to identify an immunodominant antigenic pep-
tide of the tumor presented by H-2Ld. This peptide, termed
AH1, was shown to be encoded by the env gene of the en-
dogenous retrovirus Moloney murine leukemia virus (Mo-
MuLV) (Huang et al., 1996). CTLs directed against this anti-
gen were also present in the spleens of animals treated with a
recombinant herpes viral vector encoding IL-12 (Toda et al.,
1998). Results shown here (Fig. 2c) confirm that at least part
of the CT26-specific CTL activity detected in our cultures was
against this antigen when using P815 cells as targets pulsed
with AH1 synthetic peptide.
The identity of the effector cells in the in vivo antitumor ac-
tivity was addressed by negative and positive selection methods.
Figure 3 displays results obtained in an experimental setting iden-
tical to the setting used in Fig. 1, but in this case CTL cultures
obtained from mice whose subcutaneous tumors had been treated
with AdCMVIL-12 were selectively depleted of CD41 or CD8 1
cells by incubation in vitro with specific MAb plus rabbit com-
plement before being used for adoptive therapy. Results show a
critical involvement for CD8 1 but not CD41 T cells.
In addition, when CD81 cells were purified from the cul-
tures by magnetic immunoselection yielding 98% purity, se-
lected cells displayed a dose-dependent antitumor effect, indi-
cating that CD8 1 T cells were the necessary and sufficient
populations for adoptive therapy (Table 1). Moreover, a lym-
phoid infiltrate was also observed in established CT26 tumors
implanted in the liver of athym ic BALB/cnude/nude mice that
were treated intravenously with this CTL culture, thus clearly
suggesting that adoptively transferred cells could home into the
tumor tissue (data not shown).
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TABLE 1. DO SE-DEP EN D EN T AN TITU M OR
EFFECT OF CD8 1 CEL LS
Tumor sizeb
CTL dosea Individual sizes Mean
0 10, 9, 20 13
2 3 104 3, 8, 8.5 6.5
2 3 105 0, 5.5, 8 4.5
2 3 106 0, 3, 2 1.7
aNumber of CD8 1 cells purified from CTL cultures by im-
munoselection with magnetic beads, adoptively transferred in-
travenously to mice hosting liver CT26 tumors 4 days prior to
adoptive therapy. Purity of CD8 1 cell suspensions was found
to be above 98% by FACS analysis.
bIndividual and mean tumor diameters, in millimeters. Size
was measured by surgical inspection of the liver on day 12 
after adoptive transfer.
FIG. 3. CD8 1 T cells are required for the antitumor effect of adoptive therapy. Cells (5 3 106) from the CTL cultures gener-
ated from draining lymph nodes of mice with subcutaneous CT26 tumors treated with AdCMVIL-12, under conditions identical
to those in Fig. 1, were adoptively transferred intravenously to mice that harbored CT26 tumors implanted 4 days previously in
the liver. In this case, prior to adoptive transfer, cultures were depleted of CD41 or CD81 T cells by in vitro treatment with anti-
CD4 MAb, anti-CD8 MAb, or medium and subsequently treated with rabbit complement. Tumor sizes were monitored 10 days
after adoptive therapy.
Adenoviral transfer of IL-12 into CT26 tumors
displays a synergistic effect with adoptive 
transfer of antitumor T lymphocytes
The preceding data show that AdCMVIL-12 treatment ben-
efits T cell adoptive therapy through its effect on the induction
of a stronger CTL response, easing the in vitro obtention of ef-
fective T cell cultures. We then explored the possibility that
AdCMVIL-12 and CTL cultures were also synergistic at the
antitum or effector phase. In this case, the CTLs (obtained un-
der culture conditions similar to those described above) were
given 5 days after the intratumoral injection of AdCMVIL-12.
A tumor model was established by injection of 5 3 105 CT26
cells, both subcutaneously in the left flank and inside the mid-
lobe of the liver. In these animals, both tumors progressed and
killed the animals if left untreated. This experiment was carried
out to mimic the frequent condition of having a local colon car-
cinoma with the suspicion of or evidence that the malignancy
has spread into the liver. In a first set of experiments, tumors
were allowed to grow for 10 days to reach a size of 4–8 mm
in both sites. Under such conditions, we verified that the for-
mation of the subcutaneous and intrahepatic tumors did not in-
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FIG. 4. Synergy of AdCMVIL-12 and T cell adoptive therapy in the treatment of distantly spread CT26 tumors. Mice hosting
two CT26 tumors, one implanted subcutaneously and the other inside the midlobe of the liver, were divided in four groups that
received the following injections: 108 PFU of AdCMVIL-12 in the subcutaneous tumor, 5 3 106 cells from the CTL cultures (in-
travenous), both treatments, or none. AdCMVIL-12 on day 10 and/or CTLs on day 15 after tumor inoculation were given to the
indicated groups. The outcome was monitored by measuring the size of the liver on day 21 after tumor engraftment (a) or by
following the survival of the different groups of mice (b). Every group received doses of 2 3 104 IU of rIL-2 intraperitoneally




terfere with each other without treatment (data not shown).
Then, as shown in Fig. 4, four groups of mice were studied.
The first group received the intravenou s injection of CTLs in
addition to the injection of AdCMVIL-12 into the subcuta-
neous tumor nodule. The other three groups received only one
of these treatm ents or none. When the liver tumors were sur-
gically inspected 10 days after the onset of treatm ent, a marked
antitumor effect was observed in the CTL 1 AdCMVIL-12
group, leading to the complete regression of the hepatic tu-
mors in 9 of 16 cases and with a clear decrease in the re-
maining tumor sizes. Single inoculation  of AdCMVIL-12 into
the subcutaneo us site, but without CTL transfer, displayed
only limited antitum or activity at the liver site. In the case of
mice receiving only CTLs, no activity was detected against
these relatively large nodules. Survival data confirmed  these
observation s (Fig. 4b) and suggested that some tumors still
detected on day 10 posttherapy  eventually regressed. It is note-
worthy that CTLs by themselves were efficacious  against
small tumor burdens (Fig. 1) but were unable to treat larger
tumor nodules (Fig. 4).
It is interesting that combined therapy also improved the ef-
fect of AdCMVIL-12 injection at the local dermal site. In the
follow-up of the subcutaneous tumor nodules, 14 of 15 cases
receiving combined therapy completely regressed whereas only
10 of 15 regressed in those mice receiving AdCMVIL-12 only
(data not shown). In the group receiving the infusion of CTLs
but without AdCMVIL-12 only 1 regression of the subcuta-
neous nodule was observed of 10 mice, in comparison with
none in the control group (data not shown). These data sug-
gested that there was also synergy between local treatm ent by
AdCMVIL-12 and the systemic administration of CTLs. To fur-
ther confirm  these observations, hepatic tumors were given an
intratumoral injection of 107 PFU of AdCMVIL-12, a dose that
had been found to be suboptimal for liver tumors implanted 10
days before treatment (G. Mazzolini, unpublished observations,
1998). Under these suboptimal conditions the intravenous in-
fusion of CTLs on day 15 after injection of tumor cells was re-
sponsible for a marked improvement in efficacy in reducing the
size of the tumors on day 21 (Fig. 5). Such data confirm the
synergy observed at the effector phase of AdCMVIL-12 1
CTLs combined therapy when studied locally at the adenovi-
rally transduced tumor site.
Recombinant adenovirus injected in the subcutaneous
tumor nodule gains access to liver parenchyma
To address the mechanisms underlying the effects on the
liver tumors induced by injecting AdCMVIL-12 into a concur-
rent subcutaneous tumor nodule, several experiments were car-
ried out. In a group of mice carrying concomitantly a subcuta-
neous CT26 tumor and intrahepatic tumor nodules, the
subcutaneous tumor was treated with 5 3 108 PFU of Ad-
CMVlacZ. Frozen sections of the midlobe of the liver of such
animals harvested 2 days later were stained for b -galactosidase
activity. On microscopic examination, scattered strongly posi-
tive cells were detected in the healthy liver parenchyma (Fig.
6B). It is interesting that an intense positive staining was de-
tected in the liver tissue surrounding tumor nodules, thus de-
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FIG. 5. Local injection of suboptimal doses of AdCMVIL-12 into a CT26 tumor nodule inside the liver synergizes with sys-
temic administration of anti-CT26 CTLs. Mice bearing a single CT26 tumor nodule in the midlobe of the liver were injected on
day 10 after tumor implantation with 107 PFU of AdCMVIL-12 with (left) or without (right) subsequent intravenous treatment
by adoptive transfer of 5 3 106 cells from the CTL cultures. Individual size of tumor nodules was assessed before AdCMVIL-
12 injection as well as 8 days after injection. Both groups received a similar regimen of treatm ent with IL-2.
picting a rim of transduced cells. Also, some cells stained pos-
itive within such malignant lesions (Fig. 6A).
In a similar setting IL-12 p70 was detected by ELISA in ho-
mogenates of liver tissue when the subcutaneous tumor had
been treated with AdCMVIL-12 (5 3 108 PFU) (Fig. 6C). Liver
IL-12 concentrations per 100 mg of tissue were at least 10 times
lower than that observed in the subcutaneous malignant nod-
ule, which received the AdCMVIL-12 dose directly (Fig. 6D).
Our data strongly suggest a role for “leaky” adenovirus
reaching the systemic circulation and eventually infecting the
liver tissue in the observed therapeutic synergy. Such a phe-
nomenon establishes a link between treatment of the subcuta-
neous tumor and the effects on the experimental metastasis in
the liver.
DISCUSSION
The present study provides evidence that the efficacy of
adoptive therapy with CTLs can be enhanced by active im-
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FIG. 6. Liver cells express the transgene encoded by a recombinant adenovirus injected into a subcutaneous tumor nodule. (A
and B) Frozen sections of livers carrying CT26 tumor nodules stained by X-Gal that had been obtained from mice carrying a
concomitant subcutaneous tumor treated with 5 3 108 PFU of AdCMVlacZ 2 days prior to liver harvest. In (A) healthy liver and
tumor nodules are shown ( 3 10) in (B) healthy liver parenchyma is shown with greater magnification ( 3 20). (C and D) IL-12
p70 concentration per 100 mg of tissue obtained by ELISA in homogenates of (C) liver tissue and (D) concomitant subcutaneous
tumor nodules injected with the indicated adenovirus or saline buffer 3 days prior to tissue collection. The concentration of IL-
12 in tissue samples treated with AdCMVlacZ or saline was under the detection threshold of the ELISA (15 pg/ml). Data are
representative of two different experim ents.
munotherapy, as provided by an IL-12-encoding adenoviral
vector. Thus, gene transfer of IL-12 into CT26 tumors improves
the yield of tumor-specific CTLs in short-term  cultures. More-
over, systemic treatm ent with those CTL cultures and infection
of the tumor tissue with AdCMVIL-12 show synergy not only
against tumor nodules transduced with the recombinant adeno-
virus but also against distant, nonadenovirally transduced tu-
mor sites.
IL-12 has been shown to promote CTL precursor expansion
and differentiation both in vitro and in vivo (Trinchieri, 1998).
Since functional IL-12 receptors (IL-12Rs) have been detected
on CD8 1 T cells, upregulation of CTL activity could result in
part from direct effects of the cytokine on this T cell subset
(Trinchieri, 1998). However, IL-12 also activates IFN- g secre-
tion and other functions from other cell types such as helper T
lymphocytes and NK cells that can subsequently promote CTL
expansion and activation (Topalian, 1994; Kos and Engleman,
1996). The importance and need of helper T populations for the
IL-12-boosted antitumor response vary with the different tumor
cell lines and experimental systems. Using IL-12 transfectants
in CT26, it has been reported that CD4 1 T cells have a dele-
terious effect on the antitumor response otherwise mediated by
CD8 1 T cells and NK cells (Martinotti et al., 1995). However,
it is conceivable that CTL generation, even in the CT26 setting,
can be favored by Th1 cells that secrete IL-2 and IFN-g
(Trinchieri, 1998) and that are able to license professional APCs
for activation of CTL precursors (Lanzavecchia, 1998; Ridge
et al., 1998). In fact, antitumor effects mediated by CD4 1 cells
have been reported by the same group when the IL-12 trans-
fectants are injected into IFN- g receptor knockout mice (Ziloc-
chi et al., 1998). In this regard, too-high doses of IL-12 have
been reported to downregulate the T cell response, acting
through an excess of IFN- g (Kurzawa Koblish et al., 1998;
Lasarte et al., 1999).
Regardless of the complexity of the mechanisms whereby IL-
12 augments the CTL response against CT26, we have observed
that anti-CT26 CTL activity could be detected only after gene
transfer of IL-12 into the tumors. Our short-term CTL lines were,
at least in part, directed to the AH1 tumor antigen encoded by
the env gene of an endogenous retrovirus, present in the genome
of normal BALB/c mice, which is expressed by the CT26 tumor
cell line (Huang et al., 1996). Similar results of specificity had
been obtained using a herpesvirus-based vector to transfer IL-12
expression into CT26 tumors in vivo (Toda et al., 1998). Our
CTL cultures did not lyse unpulsed P815 cells or YAC-1 cells,
thus excluding lack of specificity. Even though CTL clones,
rather than short-term CTL lines are usually preferred for T cell
adoptive therapy, an early-passaged CTL line may be advanta-
geous in preventing tumor antigen escape variants, because they
are less selected by immunodominant antigens and can recog-
nize more than one epitope. Experimentation in progress in our
laboratory is comparatively testing the use of long-term versus
short-term CTL lines in various in vivo tumor models.
Adoptive T cell therapy (Ridell and Greenberg, 1995; Yee
et al., 1997) against tumor antigens has been successfully used
in a number of cases (Kast et al., 1989; Lynch and Miller, 1991;
Ridell and Greenberg, 1995; Yee et al., 1997). We show that
short-term CTL cultures from mice whose tumors were under-
going AdCMVIL-12-induce d regression displayed a potent ef-
fect against small CT26 tumors implanted as cell suspensions
in the liver, 4 days prior to adoptive therapy. Such an effect
was not observed in identical lymphocyte cultures obtained
from CT26 tumor-bearing animals treated with a control adeno-
virus or left untreated, indicating the dependence of CTL ac-
tivity on the expression of the IL-12 transgene. These data im-
ply that intratumoral treatment with AdCMVIL-12 simplifies
the subsequent in vitro growth of effective CTLs. Although
adoptively transferred CD4 1 cells have displayed antitumor ac-
tivity in some systems (Hu et al., 1993), the presence of CD4 1
T cells in our adoptively transferred cultures is not a require-
ment and only the depletion of CD8 1 cells abrogated their in
vitro and in vivo activity. Moreover, purified CD8 1 cells from
those cultures were sufficient to execute, in a dose-dependent
manner, the antitum or effect on adoptive transfer. These results
exclude a relevant role for other minor cell populations such as
dendritic cells that could be present in our short-term T cell 
cultures. As a broader interpretation of these experiments, we
postulate that protocols of adoptive immunotherap y will bene-
fit from previous active immunotherapy approaches perform ed
on the same patient, which thereby augment the number of re-
sponding T cells available for their subsequent in vitro expan-
sion. Among the candidates for those active therapy procedures
are the gene transfer of cytokines or costimulatory molecules
to the tumor mass (Chen et al., 1993) and/or vaccination with
tumor antigens presented by dendritic cells (Mayordomo et al.,
1995). However, we cannot confirm that adoptively transferred
antitum or CTLs carry out their effects only the basis of their
tumor-specific cytolytic potential since their ability to secrete
different cytokines can also be involved.
Intratumoral injection of AdCMVIL-12 into CT26 tumors
causes tumor regressions in 60–80% of cases (Mazzolini et al.,
1999). In several systems it has been shown that IFN-g is the
main downstream mediator of the IL-12 antitumor effects. In
the liver, a key role for NK T cells as a source of IFN- g in the
antitum or response induced by IL-12 has been identified using
gene-targeted mice (Cui et al., 1997). IFN-g in turn induces a
plethora of effects not only on immune system cells but also
on tumor cells, making them prone to be lysed by CTLs (Cough-
lin et al., 1998). Evidence shows that the chemokines IP-10 and
Mig (monokine induced by IFN-g ) are induced by IFN- g , on
administration of IL-12, and mediate a potent tumor angiogen-
esis inhibition, while theoretically they also drive activated T
cells to the tumor tissue.
Experiments carried out in mice bearing two distant tumor
nodules, subcutaneous and intrahepatic, have found that injec-
tion of AdCMVIL-12 in one tumor site (subcutaneous nodule)
has therapeutic effects on the second nodule, but only in a mi-
nority of cases. In contrast with the timid therapeutic effect on
the liver tumor induced by AdCMVIL-12 injected into the sub-
cutaneous nodule, combined administration of intravenously,
adoptively transferred CTLs and injection of AdCMVIL-12 in
the subcutaneous tumor nodule causes a dramatic antitumor ef-
fect against relatively large, well-established  intrahepatic
metastasis and further improved the outcome of subcutaneous
tumor nodules themselves. Our current research is trying to dis-
entangle the main molecular mechanisms behind the observa-
tion of the synergy phenomenon. A major question is whether
IL-12 and/or IFN-g can act at the distant, nonadenovirally trans-
duced tumor site. In some reported models (Bramson et al.,
1997) and in our hands, a fraction of the adenovirus injected
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into the tumor gains access to the systemic circulation and in-
fects the healthy liver parenchyma, giving rise to expression of
the transgene. Secretion of IL-12 in the liver can set in motion a
cascade of proinflammatory cytokines potentially cooperative
with adoptively transferred CTLs and with direct antitumor ac-
tivity. The above-mentioned studies of NK T cell-deficient mice
(Cui et al., 1997) predict a role for these liver-located lympho-
cytes in the overall process that is being addressed. If this sce-
nario of local cytokine secretion inside the liver is important for
the observed synergistic effect, then it might be advantageous to
treat liver metastasis but perhaps not as powerful to treat the ex-
tension of the disease to other organs. Nonetheless, liver metas-
tases are frequent, often fatal, complications of colon cancer. It
is interesting that transgene-expressing cells were much more fre-
quent in the liver tissue located in the immediate neighborhood
of the malignant nodules. Such transduced cells form a sort of
rim around the tumor nodules and could be involved in the ob-
served therapeutic effects. Our current research is dealing with
the molecular mechanisms explaining the selectivity of infection
around the malignant tissue.
IL-2 and other cytokines are routinely used to potentiate
adoptive therapy. In our protocols we injected rIL-2 intraperi-
toneally in all the experimental groups because of the belief that
fully differentiated CTLs cannot produce IL-2 (Kast et al.,
1989; Lynch and Miller, 1991; Ridell and Greenberg, 1995;
Yee et al., 1997). Along this line, data show that coinjection
into tumor tissue of two different recombinant adenoviruses en-
coding IL-12 and IL-2 had a marked synergistic effect (Addi-
son et al., 1998), which likewise had been observed with the
recombinant cytokines. However, the IL-2 doses given in our
adoptive transfer protocols did not display measurable antitu-
mor activity by themselves.
Our preliminary data indicate that AdCMVIL-12 injection
into a subcutaneous CT26 tumor enhances the expression of
vascular cell adhesion molecule 1 (VCAM-1) on the endothe-
lial cells present within concomitant liver tumor nodules. We
are exploring whether this phenom enon favors the homing of
antitum or lymphocytes into malignant tissue as has been sug-
gested (Ogawa et al., 1997), thus providing a mechanistic view
of the observed effector-phase synergy (G. Mazzolini, unpub-
lished observations, 1998). In light of the data showing ex-
pression of the transgene in the liver, the IL-12-triggered cas-
cade of cytokines might be responsible for this local
upregulation of VCAM-1.
Taken together, our data provide evidence of a potent syn-
ergy between T cell adoptive therapy and gene transfer of IL-
12 into tumor tissue. Both therapies cooperate at least at two
different levels: (1) AdCMVIL-12 treatment enhances CTL re-
sponses and facilitates their in vitro culture; and (2) systemic
administration of CTLs and local treatment with AdCMVIL-12
display a potent effect against metastatic disease. Such a com-
bined therapeutic strategy, rather than having an additive ef-
fect, shows a powerful synergy that should not be overlooked
in the design of future clinical applications.
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